Liraglutide tracker
Educational reference for Liraglutide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
13 h
Tmax
11 h
Category
glp1
> PLACEHOLDER — pending clinical review by licensed pharmacist. Liraglutide is a once-daily GLP-1 receptor agonist whose fatty-acid side chain enables albumin binding sufficient for a 13-hour half-life but not once-weekly dosing. It was the first GLP-1 RA approved for weight management (Saxenda) and remains widely used for type 2 diabetes (Victoza). Its shorter half-life means daily injection is required, which can be an advantage for patients who prefer tighter control over drug exposure or who experience side effects with longer-acting agents. Common injection sites are the abdomen, thigh, and upper arm. Tracking daily doses, nausea patterns, and weight trends helps patients and clinicians find the right dose schedule.
Mechanism
A GLP-1 receptor agonist with a fatty-acid acylation that promotes albumin binding and extends its half-life to allow once-daily dosing. Like other GLP-1 agonists it is associated with glucose-dependent insulin secretion, slowed gastric emptying, and reduced appetite.
Research summary
Approved for type 2 diabetes (LEAD program; cardiovascular outcomes in LEADER) and, at a higher dose, for chronic weight management (SCALE program). Marketed as Victoza for diabetes and Saxenda for weight management.
Dosing in the literature
Trials evaluated once-daily subcutaneous administration with titration. Specific regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary.
Reported side effects
Gastrointestinal effects (nausea, vomiting, diarrhea) are most commonly reported. Prescribing information includes warnings such as thyroid C-cell tumor risk in rodents and pancreatitis. This is not a complete safety profile.
Stacking notes
Combination with insulin or sulfonylureas raises hypoglycemia considerations and is a clinical decision.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- LEADER cardiovascular outcomes trial and SCALE weight-management trials · New England Journal of Medicine (2016)search PubMed for liraglutide LEADER / SCALE
- Victoza / Saxenda prescribing information · FDA prescribing information (2014)available via DailyMed / accessdata.fda.gov
References
- Liraglutide PK reviewDOI: 10.2165/00003088-200948010-00003
Track Liraglutide in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.